Chromomycose en Guadeloupe

Levang, J.; Muller, P.; Marreel, A.; Nicolas, M.; Puzenat, E.; Aubin, F.; Humbert, P

doi:10.1016/j.annder.2006.06.001

Cited by 10 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 26 articles were identified which described 1,628 patients who were documented in Mexico (603 cases) [ 16 ], Dominican Republic (450 cases) [ 17 ], Cuba (319 cases) [ 18 – 25 ], Costa Rica (153 cases) [ 26 – 30 ], Honduras (52 cases) [ 31 – 34 ], Jamaica (31 cases) [ 35 ], Panama (8 cases) [ 36 – 39 ], Puerto Rico (7 cases) [ 40 ], and Guadalupe Islands (5 cases) [ 41 ]. Data from the Dominican Republic relies on a single publication from Isa-Isa, who mentioned 450 cases since 1966 without further details [ 17 ].…”

Section: Resultsmentioning

confidence: 99%

The global burden of chromoblastomycosis

et al. 2021

View full text Add to dashboard Cite

Background Chromoblastomycosis (CBM), represents one of the primary implantation mycoses caused by melanized fungi widely found in nature. It is characterized as a Neglected Tropical Disease (NTD) and mainly affects populations living in poverty with significant morbidity, including stigma and discrimination. Methods and findings In order to estimate the global burden of CBM, we retrospectively reviewed the published literature from 1914 to 2020. Over the 106-year period, a total of 7,740 patients with CBM were identified on all continents except Antarctica. Most of the cases were reported from South America (2,619 cases), followed by Africa (1,875 cases), Central America and Mexico (1,628 cases), Asia (1,390 cases), Oceania (168 cases), Europe (35 cases), and USA and Canada (25 cases). We described 4,022 (81.7%) male and 896 (18.3%) female patients, with the median age of 52.5 years. The average time between the onset of the first lesion and CBM diagnosis was 9.2 years (range between 1 month to 50 years). The main sites involved were the lower limbs (56.7%), followed by the upper limbs (19.9%), head and neck (2.9%), and trunk (2.4%). Itching and pain were reported by 21.5% and 11%, respectively. Malignant transformation was described in 22 cases. A total of 3,817 fungal isolates were cultured, being 3,089 (80.9%) Fonsecaea spp., 552 (14.5%) Cladophialophora spp., and 56 Phialophora spp. (1.5%). Conclusions and significance This review represents our current knowledge on the burden of CBM world-wide. The global incidence remains unclear and local epidemiological studies are required to improve these data, especially in Africa, Asia, and Latin America. The recognition of CBM as NTD emphasizes the need for public health efforts to promote support for all local governments interested in developing specific policies and actions for preventing, diagnosing and assisting patients.

show abstract

Section: Resultsmentioning

confidence: 99%

The global burden of chromoblastomycosis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This explains the frequency of involvement of the lower limb, but other locations, such as upper limbs, buttocks, trunk and face, have been reported. [1,2,4] Clinically, nodules,, patches, warty plaques,, tumors, and scars have been described [1,3,5]. Our patient did not recall trauma but was engaged in an occupation associated with frequent trauma.…”

Section: Discussionmentioning

confidence: 75%

“…There are 5 species: Fonsecaea pedrosoi, Carrionii Cladosporium, Phialophora verrucosa, Fonsecaea Compacta, and Rhinocladiella aquaspersa. [1,2] Chromomycosis is a cosmopolitan disease, but mainly prevalent in tropical and subtropical regions. Chromomycosis is exceptional in North Africa; only ten cases have been reported in Morocco between 1989 and 2010, nine of which were related to F. pedrosoi.…”

Section: Discussionmentioning

confidence: 99%

“…Seven cases have been described in Algeria and two in Tunisia. [1,2,3] The infection affects mostly men in rural areas as a result of skin injury by plant thorns or contaminated wood chips. This explains the frequency of involvement of the lower limb, but other locations, such as upper limbs, buttocks, trunk and face, have been reported.…”

Section: Discussionmentioning

confidence: 99%

“…Terbinafine is a useful first-line treatment in chromomycosis; the dosage of terbinafine ranges from 250 mg to 1 g per-day, for 6 months to one year, until achievement of a negative mycological examination. [1,2,3,6,7,8]…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations